IBSA USA
Ray Dean is an experienced sales professional with a strong background in pharmaceutical sales and marketing. Currently serving as the Regional Sales Manager for the West at IBSA USA since April 2022, Ray previously held similar roles at IBSA Pharma Inc. and IQVIA from August 2018 to April 2022. Prior to that, Ray worked as a National Account Manager and held multiple positions at Akrimax Pharmaceuticals, including Director of Marketing and Regional Sales Manager. With additional experience as Director of Sales Operations and District Manager at Pamlab, and a marketing role at Reliant Pharmaceuticals, Ray has developed a comprehensive skill set in sales leadership and operational oversight. Ray holds a degree from Shippensburg University of Pennsylvania, obtained between 1995 and 1999.
This person is not in any teams
IBSA USA
IBSA USA is the subsidiary of IBSA Group, the largest privately owned pharmaceutical company in Switzerland. IBSA is committed to improving patient quality of life through research, innovation, and the development of effective drugs and cutting-edge technologies. IBSA USA markets two unique levothyroxine formulations in the U.S. for the treatment of hypothyroidism: Tirosint® (levothyroxine sodium) capsules and Tirosint®-SOL (levothyroxine sodium) oral solution. IBSA also markets Licart™ (diclofenac epolamine) topical system 1.3%, the only once-a-day topical nonsteroidal anti-inflammatory (NSAID) available in the U.S. to treat acute pain due to minor strains, sprains, and contusions. IBSA is focused on the health and well-being of patients and driven by the desire to bring therapeutic alternatives to as many people as possible. IBSA Group bases its philosophy on four sustainable pillars: Person, Innovation, Quality, and Responsibility. For more information about Tirosint, Tirosint-SOL, or Licart, including Full Prescribing Information, go to each brand’s respective website.